Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A G Kermode

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
European Journal of Neurology|April 1, 2018
Association of serum Cystatin C with neuromyelitis optica spectrum disordersY Shu, L Zhang, Y Chang, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 1, 1991
Destructive lesions in demyelinating diseaseB D Youl, A G Kermode, A J Thompson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 18, 2013
A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)W M Carroll, T Saida, H J Kim, et al.
Neurology|February 1, 1990
Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancementA G Kermode, P S Tofts, A J Thompson, et al.
Data in Brief|March 10, 2017
Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosisN Fewings, P N Gatt, F C McKay, et al.
Journal of Autoimmunity|January 9, 2017
The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosisN L Fewings, P N Gatt, F C McKay, et al.
The Pharmacogenomics Journal|March 23, 2016
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association studyS Mahurkar, M Moldovan, V Suppiah, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
European Journal of Neurology|April 1, 2018
Association of serum Cystatin C with neuromyelitis optica spectrum disordersY Shu, L Zhang, Y Chang, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 1, 1991
Destructive lesions in demyelinating diseaseB D Youl, A G Kermode, A J Thompson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 18, 2013
A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)W M Carroll, T Saida, H J Kim, et al.
Neurology|February 1, 1990
Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancementA G Kermode, P S Tofts, A J Thompson, et al.
Data in Brief|March 10, 2017
Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosisN Fewings, P N Gatt, F C McKay, et al.
Journal of Autoimmunity|January 9, 2017
The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosisN L Fewings, P N Gatt, F C McKay, et al.
The Pharmacogenomics Journal|March 23, 2016
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association studyS Mahurkar, M Moldovan, V Suppiah, et al.
Pageof 5